JNJ
Johnson & Johnson insider trading
Health Care · Net selling
Close · Oct 5, 2026
$252.93
+37.5% over 12 months
Share price and insider trades
JNJ closeInsider buyInsider sale
Bought, 12 months$258K
Sold, 12 months$155M
Insiders buying1
Insiders selling10
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit+$58KOn all tracked purchases +22.7%
Summary
Over the past 12 months, 1 Johnson & Johnson insider reported open-market purchases totaling $258K, while 10 insiders reported sales totaling $155M. 0 of 29 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 114 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 4SEC | Timothy SchmidChair | Sell | 22,527 | $274.74 | $6.2M | -7.9% | — |
| Sep 4SEC | Timothy SchmidChair | Sell | 11,070 | $274.74 | $3.0M | -7.9% | — |
| Aug 18SEC | Jennifer L TaubertEvp, Wwc. Innovative Medicine | Sell | 15,000 | $263.36 | $4.0M | -4.0% | — |
| Aug 14SEC | Joaquin DuatoCEO, Chair | Sell | 102,315 | $261.00 | $26.7M | -3.1% | — |
| Aug 14SEC | Joaquin DuatoCEO, Chair | Sell | 20,976 | $262.00 | $5.5M | -3.5% | — |
| Aug 7SEC | Joaquin DuatoCEO, Chair | Sell | 41,957 | $258.06 | $10.8M | -2.0% | — |
| Aug 7SEC | Elizabeth ForminardGeneral Counsel | Sell | 9,344 | $257.75 | $2.4M | -1.9% | — |
| Aug 7SEC | Joaquin DuatoCEO, Chair | Sell | 6,523 | $258.74 | $1.7M | -2.2% | — |
| Aug 7SEC | Elizabeth ForminardGeneral Counsel | Sell | 6,574 | $255.93 | $1.7M | -1.2% | — |
| Jul 21SEC | Vanessa BroadhurstEvp, Global Corp Affairs | Sell | 23,054 | $251.27 | $5.8M | +0.7% | — |
| Jun 12SEC | Kathryn E WengelEvp, Chief To And Risk Officer | Sell | 10,000 | $241.15 | $2.4M | +4.9% | — |
| Mar 3SEC | Robert J DeckerVp Corporate Controller | Sell | 4,075 | $247.87 | $1.0M | +2.0% | — |
| Feb 23SEC | Timothy SchmidChair | Sell | 1,322 | $245.66 | $325K | +3.0% | — |
| Feb 18SEC | Joseph J WolkCFO | Sell | 33,386 | $242.75 | $8.1M | +4.2% | — |
| Feb 18SEC | John C ReedEvp, Innovative Medicine, R&D | Sell | 29,927 | $243.00 | $7.3M | +4.1% | — |
| Feb 18SEC | Joseph J WolkCFO | Sell | 24,961 | $242.68 | $6.1M | +4.2% | — |
| Feb 18SEC | James D. SwansonEvp, Cio | Sell | 22,191 | $243.71 | $5.4M | +3.8% | — |
| Feb 18SEC | John C ReedEvp, Innovative Medicine, R&D | Sell | 21,721 | $243.00 | $5.3M | +4.1% | — |
| Feb 18SEC | James D. SwansonEvp, Cio | Sell | 20,521 | $242.70 | $5.0M | +4.2% | — |
| Feb 18SEC | James D. SwansonEvp, Cio | Sell | 19,368 | $243.76 | $4.7M | +3.8% | — |
| Feb 18SEC | Joseph J WolkCFO | Sell | 19,241 | $242.99 | $4.7M | +4.1% | — |
| Feb 18SEC | Timothy SchmidChair | Sell | 13,625 | $244.20 | $3.3M | +3.6% | — |
| Feb 18SEC | Joseph J WolkCFO | Sell | 12,066 | $242.87 | $2.9M | +4.1% | — |
| Feb 18SEC | Timothy SchmidChair | Sell | 8,998 | $244.53 | $2.2M | +3.4% | — |
| Feb 18SEC | Vanessa BroadhurstEvp, Global Corp Affairs | Sell | 6,197 | $243.39 | $1.5M | +3.9% | — |
| Feb 18SEC | John C ReedEvp, Innovative Medicine, R&D | Sell | 2,283 | $243.00 | $555K | +4.1% | — |
| Jan 28SEC | Joaquin DuatoCEO, Chair | Sell | 51,218 | $220.99 | $11.3M | +14.5% | — |
| Jan 28SEC | Joaquin DuatoCEO, Chair | Sell | 48,782 | $221.48 | $10.8M | +14.2% | — |
| Dec 1SEC | John G MorikisDirector | Buy | 1,250 | $206.15 | $258K | +22.7% | — |
| Oct 20SEC | John C ReedEvp, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.2M | +31.3% | — |
Insiders at Johnson & Johnson
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Joaquin DuatoCEO, Chair | — | $66.8M | Aug 14, 2026 | — |
| Joseph J WolkCFO | — | $21.8M | Feb 18, 2026 | — |
| John C ReedEvp, Innovative Medicine, R&D | — | $17.3M | May 4, 2026 | — |
| James D. SwansonEvp, Cio | — | $15.1M | Feb 18, 2026 | — |
| Timothy SchmidChair | — | $15.1M | Sep 4, 2026 | — |
| Vanessa BroadhurstEvp, Global Corp Affairs | — | $7.3M | Jul 21, 2026 | — |
| Elizabeth ForminardGeneral Counsel | — | $4.1M | Aug 7, 2026 | — |
| Jennifer L TaubertEvp, Wwc. Innovative Medicine | — | $4.0M | Aug 18, 2026 | — |
| Kathryn E WengelEvp, Chief To And Risk Officer | — | $2.4M | Jun 12, 2026 | — |
| Robert J DeckerVp Corporate Controller | — | $1.0M | Mar 3, 2026 | — |
| John G MorikisDirector | $258K | — | Dec 1, 2025 | — |
| Kristen MulhollandEvp, Chief Hr Officer | — | — | Feb 18, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about JNJ insiders
Are Johnson & Johnson insiders buying JNJ stock?
In the past 12 months, 1 insiders reported open-market purchases of JNJ worth $258K. The latest was Director John G Morikis bought $258K of JNJ at $206.15 — first open-market purchase in our records; raises the stake by 209%.
Are Johnson & Johnson insiders selling JNJ stock?
10 insiders reported sales worth $155M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.